Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans.
about
Kidney disease: new technologies translate mechanisms to cureThe Renal Sodium Bicarbonate Cotransporter NBCe2: Is It a Major Contributor to Sodium and pH Homeostasis?The importance of the gastrorenal axis in the control of body sodium homeostasisTenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers.Hypertension Treatment for Patients with Advanced Chronic Kidney Disease.Gastrointestinal Inhibition of Sodium-Hydrogen Exchanger 3 Reduces Phosphorus Absorption and Protects against Vascular Calcification in CKD.Gut microbiota in hypertension.Physiology of Intestinal Absorption and Secretion.Role of enteroendocrine L-cells in arginine vasopressin-mediated inhibition of colonic anion secretion.Pathophysiology of Intestinal Na+/H+ exchange.Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome.New pharmacological treatment options for irritable bowel syndrome with constipation.Tenapanor administration and the activity of the H+ -coupled transporter PepT1 in healthy volunteers.Intestinal SGLT1 in metabolic health and disease.Interventional procedures and future drug therapy for hypertension.Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study.Novel developments in differentiating the role of renal and intestinal sodium hydrogen exchanger 3.Gastrointestinal-Renal Axis: Role in the Regulation of Blood PressureGastrointestinal Tract: a Promising Target for the Management of Hypertension.Understanding the Two Faces of Low-Salt Intake.Diet induced obesity in rats reduces NHE3 and Na(+) /K(+) -ATPase expression in the kidney.Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis.The importance of intake: a gut feeling.Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate Binders.Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions.Role of intestinal Na(+)/H(+) exchanger inhibition in the prevention of cardiovascular and kidney disease.New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.Na+ /H+ exchanger 3 blockade ameliorates type 2 diabetes mellitus via inhibition of sodium-glucose co-transporter 1-mediated glucose absorption in the small intestine.Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers.Development and Characterization of a Human and Mouse Intestinal Epithelial Cell Monolayer Platform.Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment.Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.
P2860
Q26825227-E0E80C5D-1BB3-4700-BF85-D2BCD78213CAQ30275942-15B10EDA-4825-42A1-B7E4-7468AD17A55CQ30277383-69631623-B2FA-4870-BE28-0033F6B58E00Q33639963-923D48BA-230C-4D11-ACCD-5F3518AF61B7Q33840387-33FB13A8-101B-4654-ACD7-C703451A45D8Q34763214-F9B3AC57-B88A-4950-AF8C-E0746CBBFEFDQ35550601-D769B086-E9F7-4BE1-9488-556C809C6B44Q36082623-8A2CE36F-C100-403B-8EAC-AC39A452136FQ37115961-04196E2B-8B96-4E34-843A-C736542D6277Q37228951-8C6F7E36-6BE2-474C-9D21-365613CA0EAEQ37585753-AE3787FE-5721-43E6-9DB1-22515CBED969Q38525007-13A71BC3-E93C-415B-A746-73FED990DED9Q38628078-9FF43B0D-91A4-4370-9079-4F8843317A78Q38692100-F01D454A-8437-4E2E-8AE3-0991704399ECQ38787917-ED48F7EC-200F-4857-A19A-AF32314D2B96Q38842624-77C7CC99-119E-4CAD-96D3-062E92BD0B6FQ38879346-49F0F36B-7C76-488D-9B91-EFA27B3FE438Q38979089-E340DAA4-C5F9-44BA-8990-E3F3F875BB95Q39164330-5316A35C-5062-4C90-813C-CC2EEB9669F3Q39204264-57E6FFA5-3CD3-4BF4-B549-1C4F9491027FQ39304736-5B000520-9284-4486-9851-7D91E4E431E4Q40738109-FA7D2CCD-404E-4650-8995-4D03D6473A16Q41022541-C970D09B-A7EF-4D80-87B7-3302E15D4AACQ41848858-F4E101A8-8167-4EC6-A97A-960B3E6C9F86Q42025679-560B0E17-F86D-420F-9337-961677226BDFQ42094433-9D7B0B99-8B36-4C76-8864-4DB20D89EA45Q42556293-339BB27C-874E-4A78-AEDF-7F5AB710A70CQ42695148-52A6720A-09D3-43EB-B365-799F5D492E28Q47432902-FD7E151B-81B4-4E37-A9EC-D18220EC6BC4Q48179198-6551D59C-94B3-4174-B652-A7B9F1347360Q49476554-64A74908-6F2B-45D7-ACE5-4D5CFAA0014CQ50093822-B5B586DE-7070-4C4F-824A-310F1BF7F0A7Q55059919-9B58CAB5-47BE-4073-910A-4DFACA5DD1CC
P2860
Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Intestinal inhibition of the N ...... inhibits Na+ uptake in humans.
@ast
Intestinal inhibition of the N ...... inhibits Na+ uptake in humans.
@en
Intestinal inhibition of the N ...... inhibits Na+ uptake in humans.
@nl
type
label
Intestinal inhibition of the N ...... inhibits Na+ uptake in humans.
@ast
Intestinal inhibition of the N ...... inhibits Na+ uptake in humans.
@en
Intestinal inhibition of the N ...... inhibits Na+ uptake in humans.
@nl
prefLabel
Intestinal inhibition of the N ...... inhibits Na+ uptake in humans.
@ast
Intestinal inhibition of the N ...... inhibits Na+ uptake in humans.
@en
Intestinal inhibition of the N ...... inhibits Na+ uptake in humans.
@nl
P2093
P2860
P1476
Intestinal inhibition of the N ...... inhibits Na+ uptake in humans
@en
P2093
Andrew G Spencer
Christopher W Carreras
Craig F Plato
David P Rosenbaum
Dominique Charmot
Eric D Labonte
Jill Kohler
Jocelyn Tabora
Kenji Kozuka
Kristin M Joly
P2860
P304
P356
10.1126/SCITRANSLMED.3007790
P407
P577
2014-03-01T00:00:00Z